A Study to Investigate the Safety and Pharmacological Effect of a Single Intravenous Infusion of Belantamab in Male and Female Participants Aged 18 to 75 With Autoimmune Disease

Sponsor
GlaxoSmithKline
Study ID
NCT06413511
Phase
PHASE1
Status
Withdrawn

Conditions

  • Autoimmune Diseases

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Belantamab — BIOLOGICAL
    Belantamab will be administered

Study Details

The goal of this clinical trial is to assess the safety and tolerability profile of belantamab. The study will also assess how the levels of belantamab change over time and body's reaction to it in participants with stable but active autoimmune disease.

Key Dates

Start date
Jun 3, 2024
Status verified
Aug 2025
Primary completion
Jul 8, 2025
Completion
Jul 8, 2025

Study Design

Enrollment
0 participants (actual)
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Belantamab

Primary Outcome Measure

Number of participants with adverse events (AEs) and serious adverse events (SAEs) [ Time Frame: Up to Week 12 ]

Related Studies